Panic Disorder

... Journal of Neuropsychiatry - Sign In Page HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH QUICK SEARCH: [advanced] Author: Keyword(s): Year: Vol: Page: This item requires a subscription to Journal of Neuropsychiatry Online.

Full Text Acquired Extroversion Associated With Bitemporal Variant of Frontotemporal Dementia Mendez et al.

J Neuropsychiatry Clin Neurosci.2006; 18: 100-107.

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a Colleague Similar articles in this journal Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Google Scholar Articles by Mendez, M.

F.

Articles by Miller, B.

L.

PubMed Articles by Mendez, M.

F.

Articles by Miller, B.

L.

Related Collections Dementias (General) To view this item, select one of the options below: Sign In User Name Sign in without cookies.

Can't get past this page?

Help with Cookies.

Need to Activate?

Password Remember my user name & password.

Forgot your user name or password?

Purchase Short-Term Access Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$15.00.

Pay for Admission - You may access all content in Journal of Neuropsychiatry Online (from the computer you are currently using) for 24 hours for US$25.00.

Regain Access - You can regain access to a recent Pay per Article or Pay for Admission purchase if your access period has n...

... Stock Market News and Investment Information RSS (Adds details, background) WASHINGTON, March 8 (Reuters) - Alexza Pharmaceuticals Inc.

(ALXA.O: Quote, Profile, Research), which focuses on the treatment of acute and intermittent conditions, on Wednesday priced its planned initial public offering of 5.5 million shares at $8 per share.

The price is lower than the range of $10 to $12 the Palo Alto, California-based pharmaceutical company had established last month.

The underwriters, led by Piper Jaffray and Pacific Growth Equities LLC, will be given the option to buy 825,000 more shares in case there is more investor demand than expected.

The pricing of shares, underwriters' allotment and other details were disclosed in an amended IPO prospectus filed with the U.S.

Securities and Exchange Commissio...

... Business Article Print This Article WASHINGTON (Reuters) - Alexza Pharmaceuticals Inc.

ALXA.O, which focuses on the treatment of acute and intermittent conditions, on Wednesday priced its planned initial public offering of 5.5 million shares at $8 per share.The price is lower than the range of $10 to $12 the Palo Alto, California-based pharmaceutical company had established last month.The underwriters, led by Piper Jaffray and Pacific Growth Equities LLC, will be given the option to buy 825,000 more shares in case ...